RecruitingNANCT07550699

Clinical Investigation to Validate the Safety and Performance of Integrating Functional Electrical Stimulation Into the ABLE Exoskeleton

Sponsor: ABLE Human Motion S.L.

Trial Details

ConditionAcquired Brain Injury (Including Stroke), Spinal Cord Injury, Multiple Sclerosis
InterventionABLE Exoskeleton with Functional Electrical Stimulation (ABLE FES)
PhaseNA
StatusRecruiting
Participants15
Est. Completion12 Aug 2026
Last Updated24 Apr 2026

Primary Outcome

Number and type of device-related Adverse Events; Time taken to don/doff the device; Number of steps walked; Distance walked; Time spent upright and time spent walking; Number of therapists assisting the session; Assistive device used; Step Length; Step Symmetry; Center of mass displacement (cm); Motor torque (Nm)

Eligibility Criteria

Inclusion Criteria

Inclusion Criteria: * 18 to 80 years old * Diagnosis of acquired brain injury, spinal cord injury (neurological level between C5 and L2, AIS B to AIS D), or multiple sclerosis * Currently undergoing physiotherapy treatment, either as an inpatient or outpatient at the investigating center * Ability to provide informed consent Exclusion Criteria: * Significant osteoporosis that may increase the risk of fracture * Unresolved fractures in the pelvis or limbs, or a history of fragility fractures in the lower limbs within the past 2 years * Spinal instability (or use of spinal orthoses, unless medically approved) * Deterioration \>3 points of the total in the motor score of the International Standards for the Neurological Classification of Spinal Cord Injury (ISNCSCI) in the last 4 weeks. Loss of sensation and/or motor activity above the level of injury detected that has not been evaluated by a doctor. * Severe spasticity: Level 4 on the Modified Ashworth Scale * Orthostatic hypotension: Inability to tolerate at least 10 minutes in an upright position * Uncontrolled autonomic dysreflexia * Medical instability * Unstable cardiovascular condition, hemodynamic instability, untreated hypertension (SBP \> 140 mmHg, DBP \> 90 mmHg), deep vein thrombosis (DVT), or uncontrolled autonomic dysreflexia * Severe comorbidities, including any condition deemed inappropriate by the investigator for using the ABLE Exoskeleton or for completing the study * Pressure ulcers Grade I or higher (as defined by the European Pressure Ulcer Advisory Panel - EPUAP) in areas that will be in contact with the device * Anthropometric measurements incompatible with the ABLE Exoskeleton, specifically height outside the 1.5-1.9 m range or weight exceeding 100 kg * Anatomical constraints (such as leg length differences, users unable to position themselves inside the device) that are incompatible with the device * Range of motion restrictions preventing normal gait or sit-to-stand transitions, including: Ankle: ability to achieve at least neutral (0°) position; Knee: ability to extend to at least -10°; Hip: bilateral hip flexion of at least 100° and extension of at least 0° * Heterotopic ossification * Pregnant or breastfeeding women * Cognitive impairment that results in the inability to follow simple instructions, particularly psychological or cognitive problems that do not allow a participant to follow study procedures * Requires assisted ventilation. * Scoliosis \>40-50º Cobb angle. * Presence of pacemakers, defibrillators, or other non-compatible electronic implants. * Open wounds, infections, or active irritation at the electrode placement sites. * Severe dermatological conditions in the stimulation area. * Uncontrolled active epilepsy. * Malignant tumors in the area of application. * Severe loss of sensation in the areas where electrodes are to be placed. * Medical conditions where electrical stimulation is contraindicated by physician recommendation. * Inability to communicate pain, discomfort, or adverse reactions during stimulation. * Venous thrombosis, thrombophlebitis, or severe arterial obstruction. * Chronic venous insufficiency with significant varicosities. * Hemophilia. * Ongoing infectious process or fever. * Presence of metallic implants in the flow area between the electrodes

Trial Sites

🇦🇺 Australian Sites (1)

Countries

Austria
View Registry Entry

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service